Fecal Microbiota Transplantation for Refractory and Recurrent Clostridium difficile Infection: A Case Series of Nine Patients.
10.4166/kjg.2017.69.4.226
- Author:
Byoung Wook BANG
1
;
Jin Seok PARK
;
Hyung Kil KIM
;
Yong Woon SHIN
;
Kye Sook KWON
;
Hea Yoon KWON
;
Ji Hyeon BAEK
;
Jin Soo LEE
Author Information
1. Division of Gastroenterology, Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea. ywshin@inha.ac.kr
- Publication Type:Original Article
- Keywords:
Fecal microbiota transplantation;
Clostridium difficile;
Colonoscopy;
Gastrointestinal microbiome
- MeSH:
Anti-Bacterial Agents;
Clostridium difficile*;
Clostridium*;
Colonoscopy;
Disease Transmission, Infectious;
Duodenoscopy;
Fecal Microbiota Transplantation*;
Follow-Up Studies;
Gastrointestinal Microbiome;
Humans;
Korea;
Pneumonia, Aspiration;
Recurrence;
Tissue Donors
- From:The Korean Journal of Gastroenterology
2017;69(4):226-231
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Fecal microbiota transplantation (FMT) is a highly effective therapy for refractory and recurrent Clostridium difficile infection (CDI). Despite its excellent efficacy and recent widespread use, FMT has not been widely used in South Korea thus far. We describe our experience with FMT to treat refractory/recurrent CDI. METHODS: We conducted a chart review of patients who underwent FMT for refractory/recurrent CDI at Inha University Hospital, between March 2014 and June 2016. The demographic information, treatment data, and adverse events were reviewed. FMT was administered via colonoscopy and/or duodenoscopy. All stool donors were rigorously screened to prevent infectious disease transmission. RESULTS: FMT was performed in nine patients with refractory/recurrent CDI. All patients were dramatically cured. Bowel movement was normalized within one week after FMT. There were no procedure-related adverse events, except aspiration pneumonia in one patient. During the follow-up period (mean 11.4 months), recurrence of CDI was observed in one patient at one month after FMT due to antibiotics. CONCLUSIONS: FMT is a safe, well-tolerated and highly effective treatment for refractory/recurrent CDI. Although there are many barriers to using FMT, we expect that FMT will be widely used to treat refractory/recurrent CDI in South Korea.
